

# **STIC Search Report**

**EIC 1700**

**STIC Database Tracking Number: 98089**

**TO: Ben Sackey**  
**Location: CM1/3B19/3D19**  
**Art Unit : 1626**  
**July 7, 2003**

**Case Serial Number: 070033**

**From: Kathleen Fuller**  
**Location: EIC 1700**  
**CP3/4 3D62**  
**Phone: 308-4290**

**Kathleen.Fuller@uspto.gov**

## **Search Notes**

Mrs Fuller

98089

Access DB#

# SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name BEM SACKET Examiner # 73489 Date: 7/3/03  
 Att Unit 1626 Phone Number 305-6889 Serial Number 16/070,033  
 Mail Box and Bldg Room Location CMT 3319 Results Format Preferred (circle) PAPER DISK E-MAIL


If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention Novel Derivatives of Dicarboxylic Acid Having Pharmaceutical Properties  
 Inventors (please provide full names) Markus Heil et al

Earliest Priority Filing Date 8/31/00

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



X and Y are each straight chain or branched alkylene having up to 6 carbon atoms.

Please also search the use of the compound or composition in treating hypertension.

Elected species is Example 16 attached to this search.

W → CH=CH

Y → -O-

T → is absent

A → COOH, CH<sub>2</sub>COOH

B → COOH, CH<sub>2</sub>COOH

R<sup>1</sup> - R<sup>3</sup> → are each hydrogen or branched alkyl chain

n → 1 to 10

m → 1 or 2

o → 1 to 5

v → 0, 1 or 2.

Points

## STAFF USE ONLY

Searcher K. Fuller

Searcher Phone #

Searcher Location

Date Searcher Requested

Date Completed 7/7/03

Searcher Preparation Time 20

Printer Prep Time

Time to Print 32

## Type of Search

NA Sequence (#)

AA Sequence (#)

Structure (#) 2

Bibliographic

Citation

Full text

Patent Family

Other

## Vendors and cost where applicable

STN ✓

Dialog

Direct Print

File Print

Link & Node

Sequence Systems

Web & Internet

Other

=> FILE REG

FILE 'REGISTRY' ENTERED AT 10:54:09 ON 07 JUL 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JUL 2003 HIGHEST RN 542812-68-0  
DICTIONARY FILE UPDATES: 4 JUL 2003 HIGHEST RN 542812-68-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 10:54:14 ON 07 JUL 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)





Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
the American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 7 Jul 2003 VOL 139 ISS 2  
FILE LAST UPDATED: 6 Jul 2003 (20030706/ED)

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> D QUE

L12 STR



VAR G1=20/15

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS MCY UNS AT 3

GGCAT IS MCY UNS AT 8

GGCAT IS MCY UNS AT 14

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L14 28 SEA FILE=REGISTRY SSS FUL L12

L15 2 SEA FILE=HCAPLUS ABB=ON L14

=&gt; D L15 ALL 1-2 HITSTR

L15 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:208229 HCAPLUS

DN 134:252150

TI Preparation of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compounds as stimulators of soluble guanylate cyclase.

IN Alonso-Alija, Cristina; Heil, Markus; Flubacher, Dietmar; Naab, Paul; Stasch, Johannes-peter; Wunder, Frank; Dembowski, Klaus; Perzborn, Elisabeth; Stahl, Elke

PA Bayer A.-G., Germany

SO PCT Int. Appl., 177 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM C07C069-00

CC 25-18 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019776	A2	20010322	WO 2000-EP8468	20000831
	WO 2001019776	A3	20011129		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

28 structures from the query

2 CA references - both applicants

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19943634	A1	20010412	DE 1999-19943634	19990913
EP 1216222	A2	20020626	EP 2000-962413	20000831

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003509399	T2	20030311	JP 2001-523357	20000831
---------------	----	----------	----------------	----------

PRAI DE 1999-19943634 A 19990913  
 WO 2000-EP8468 W 20000831  
 OS MARPAT 134:252150  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Use of compds. which are capable of stimulating sol. guanylate cyclase independently of the heme group it contains for prepn. of drugs for treatment of cardiovascular diseases such as angina pectoris, ischemia, and heart failure is claimed. Title compds. [I; B = tetrazolyl, tetrazolylmethylene, CO<sub>2</sub>H, CH<sub>2</sub>CO<sub>2</sub>H, cyano, etc.; T, V = null, O; W = CH<sub>2</sub>CH<sub>2</sub>, CH:CH, (CH<sub>2</sub>)<sub>3</sub>, CH<sub>2</sub>CH:CH; X, Y = null, alkylene, O, SCH<sub>2</sub>, S, SO, SO<sub>2</sub>; R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> = H, alkyl, alkoxy, halo, CF<sub>3</sub>, OCF<sub>3</sub>, cyano; m = 1, 2; n = 1-10; p = 1-5; q = 0-2; with provisos], are claimed. Thus, title compd. (II) showed smooth muscle relaxation in rabbit arterial rings with IC<sub>50</sub> = 0.35 nM.

ST phenylcarboxybenzyloctanoate prepn soluble guanylate cyclase inhibitor; cardiovascular agent phenylcarboxybenzyloctanoate prepn; fibrosis treatment phenylcarboxybenzyloctanoate prepn

IT Heart, disease  
 (angina pectoris, treatment; prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

IT Carboxylic acids, preparation  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (dicarboxylic; prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

IT Vein  
 (disease, treatment; prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

IT Liver, disease  
 (fibrosis, treatment; prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

IT Antiartherosclerotics  
 Anticoagulants  
 Antihypertensives  
 Cardiovascular agents  
 (prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

IT Fibrosis  
 Ischemia  
 (treatment; prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

IT 330823-26-2P 330823-27-3P 330823-28-4P 330823-29-5P 330823-30-8P

330823-31-9P 330823-32-0P 330823-33-1P 330823-34-2P 330823-35-3P  
**330823-36-4P 330823-37-5P** 330823-39-7P  
**330823-41-1P 330823-43-3P 330823-45-5P**  
**330823-47-7P 330823-49-9P 330823-50-2P**  
**330823-51-3P** 330823-52-4P **330823-53-5P** 330823-54-6P  
 330823-55-7P **330823-56-8P** 330823-57-9P 330823-58-0P  
 330823-59-1P 330823-60-4P 330823-62-6P 330823-64-8P 330823-65-9P  
**330823-66-0P 330823-67-1P 330823-68-2P**  
**330823-69-3P 330823-70-6P** 330823-71-7P 330823-72-8P  
 330823-73-9P 330823-74-0P 330823-75-1P 330823-76-2P 330823-77-3P  
 330823-78-4P 330823-79-5P 330823-80-8P 330823-81-9P 330823-82-0P  
 330823-83-1P 330823-84-2P 330823-85-3P **330823-86-4P**  
 330823-87-5P 330823-88-6P **330823-89-7P 330823-90-0P**  
 330823-91-1P 330823-92-2P **330823-93-3P** 330823-94-4P  
 330823-95-5P 330823-96-6P 330823-97-7P 330823-98-8P 330823-99-9P  
 330824-00-5P 330824-01-6P 330824-02-7P 330824-03-8P 330824-04-9P  
 330824-05-0P 330824-06-1P 330824-07-2P 330824-08-3P 330824-09-4P  
 330824-10-7P 330824-11-8P 330824-12-9P 330824-13-0P 330824-14-1P  
 330824-79-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

IT 90-01-7, 2-Hydroxybenzyl alcohol 90-02-8, Salicylaldehyde, reactions  
 96-32-2, Methyl bromoacetate 99-76-3, Methyl 4-hydroxybenzoate  
 100-39-0, Benzyl bromide 103-63-9, Phenethyl bromide 104-81-4,  
 4-Methylbenzyl bromide 104-83-6, 4-Chlorobenzyl chloride 402-49-3,  
 4-Trifluoromethylbenzyl bromide 459-46-1, 4-Fluorobenzyl bromide  
 588-63-6, 3-Phenoxy-1-bromopropane 589-15-1, 4-Bromobenzyl bromide  
 611-17-6, 2-Chlorobenzyl bromide 612-13-5, 2-Cyanobenzyl chloride  
 637-59-2, 1-Phenyl-3-bromopropane 835-78-9, 2-(2-Phenylethyl)benzyl  
 alcohol 1200-03-9, 4-Phenoxy-1-bromobutane 1467-05-6, 4-Ethylbenzyl  
 chloride 1586-00-1, 2-Benzylbenzyl alcohol 1797-75-7, Diallyl malonate  
 2417-73-4, Methyl 2-bromomethylbenzoate 3095-95-2 3337-59-5, Methyl  
 3,5-dichloro-4-hydroxybenzoate 7405-12-1, 2-Hydroxy-4-methylbenzyl  
 alcohol 13398-94-2, 2-(3-Hydroxyphenyl)ethanol 13633-25-5,  
 4-Phenylbutyl bromide 14469-83-1, 5-Phenylpentyl bromide 14525-71-4  
 18880-00-7, 4-tert-Butylbenzyl bromide 20443-98-5, 2,6-Dichlorobenzyl  
 bromide 27976-27-8, 6-Phenylhexyl bromide 34040-63-6 34040-64-7,  
 Methyl 4-(chloromethyl)benzoate 35444-44-1, Adipic acid monomethyl ester  
 chloride 64407-07-4 70340-04-4 84109-76-2 126907-58-2  
 329980-75-8 330824-77-6 330824-78-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

IT 3381-87-1P 108683-50-7P 116585-12-7P 126907-30-0P 126907-51-5P  
 135055-19-5P 135055-35-5P 212116-73-9P 329979-13-7P 329979-15-9P  
 329980-67-8P 329980-68-9P 329980-69-0P 329980-70-3P 330824-15-2P  
 330824-16-3P 330824-17-4P 330824-18-5P 330824-19-6P 330824-20-9P  
 330824-22-1P 330824-23-2P 330824-24-3P 330824-25-4P 330824-26-5P  
 330824-27-6P 330824-28-7P 330824-29-8P 330824-30-1P 330824-31-2P  
 330824-32-3P 330824-33-4P 330824-34-5P 330824-35-6P 330824-36-7P  
 330824-37-8P 330824-38-9P 330824-39-0P 330824-40-3P 330824-42-5P  
 330824-45-8P 330824-46-9P 330824-47-0P 330824-48-1P 330824-49-2P  
 330824-50-5P 330824-51-6P 330824-52-7P 330824-53-8P 330824-54-9P  
 330824-55-0P 330824-56-1P 330824-57-2P 330824-58-3P 330824-59-4P  
 330824-60-7P 330824-61-8P 330824-62-9P 330824-63-0P 330824-64-1P

330824-65-2P 330824-66-3P 330824-67-4P 330824-68-5P 330824-69-6P  
 330824-70-9P 330824-71-0P 330824-72-1P 330824-73-2P 330824-74-3P  
 330824-75-4P 330824-76-5P 330825-15-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

IT 9054-75-5, Guanylate cyclase

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(stimulators; prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

IT 330823-36-4P 330823-37-5P 330823-41-1P

330823-43-3P 330823-45-5P 330823-47-7P

330823-49-9P 330823-50-2P 330823-51-3P

330823-53-5P 330823-56-8P 330823-66-0P

330823-67-1P 330823-68-2P 330823-69-3P

330823-70-6P 330823-86-4P 330823-89-7P

330823-90-0P 330823-93-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 8-phenyl-6-(4-carboxybenzyl)octanoates and related compds. as stimulators of sol. guanylate cyclase)

RN 330823-36-4 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-(phenylmethoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-37-5 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[4-methyl-2-(phenylmethoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 330823-41-1 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[(2-

chlorophenyl)methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-43-3 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-(3-phenylpropoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-45-5 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[(5-phenylpentyl)oxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 330823-47-7 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-(2-phenylethoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 330823-49-9 HCAPLUS

CN Benzenheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[(6-phenylhexyl)oxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-50-2 HCAPLUS

CN Benzenhexanoic acid, 4-carboxy-.delta.-[(1E)-2-[2-[(5-phenylpentyl)oxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-51-3 HCAPLUS

CN Benzenheptanoic acid, .epsilon.-[(1E)-2-[2-[(4-bromophenyl)methoxy]phenyl]ethenyl]-4-carboxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-53-5 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-(4-phenylbutoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-56-8 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[(2,6-dichlorophenyl)methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-66-0 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-(4-chlorophenyl)methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-67-1 HCAPLUS

CN Benzenheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[[4-(1,1-dimethylethyl)phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-68-2 HCAPLUS

CN Benzenheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[(4-ethylphenyl)methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-69-3 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-70-6 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[[4-(4-fluorophenyl)methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-86-4 HCAPLUS

CN Benzeneheptanoic acid, 3-carboxy-.epsilon.-[ (1E)-2-[2-[(5-phenylpentyl)oxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 330823-89-7 HCAPLUS


CN Benzenebutanoic acid, 3-carboxy-.beta.-[ (1E)-2-[2-[(5-phenylpentyl)oxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 330823-90-0 HCAPLUS


CN Benzenebutanoic acid, 2-carboxy-.beta.-[2-[2-[(5-phenylpentyl)oxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 330823-93-3 HCAPLUS

CN Benzeneheptanoic acid, 2-carboxy-.epsilon.-[(1E)-2-[2-[(5-phenylpentyl)oxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:179724 HCAPLUS

DN 134:237303

TI Preparation of carboxybenzylalkanoates as stimulators of soluble guanylate cyclase.

IN Alonso-Alija, Cristina; Heil, Markus; Flubacher, Dietmar; Naab, Paul; Stasch, Johannes-peter; Wunder, Frank; Dembowski, Klaus; Perzborn, Elisabeth; Stahl, Elke

PA Bayer AG, Germany

SO Ger. Offen., 138 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM C07C065-28

ICS C07C069-76; C07C229-38; C07C065-21; C07C217-36; C07D213-63; C07D227-04; C07D247-00; C07D269-00; C07D333-06; A61K031-19

CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1, 28

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19943636	A1	20010315	DE 1999-19943636	19990913
	WO 2001019778	A1	20010322	WO 2000-EP8466	20000831
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

BR 2000014178 A 20020514 BR 2000-14178 20000831  
 EP 1216223 A1 20020626 EP 2000-964067 20000831  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL  
 JP 2003509400 T2 20030311 JP 2001-523359 20000831  
 PRAI DE 1999-19943636 A 19990913  
 WO 2000-EP8466 W 20000831  
 OS MARPAT 134:237303  
 AB Use of compds. which stimulate sol. guanylate cyclase independently of the  
 heme group in the enzyme for prepn. of drugs for treatment of  
 cardiovascular diseases such as angina pectoris, ischemia, and heart  
 failure is claimed. Thus, 2-methoxybenzyltriphenylphosphonium bromide in  
 THF at 0.degree. was treated with BuLi; after 30 min. Me  
 6-formyl-7-(4-methoxycarbonylphenyl)heptanecarboxylate in THF was added  
 followed by stirring for 30 min. at 0.degree. to give 25.8% Me  
 6-(4-methoxycarbonylbenzyl)-8-(2-methoxyphenyl)-7-octenoate. Title  
 compds. showed blood vessel relaxing activity with IC50 = 0.2-3500 nM.  
 ST carboxybenzylalkanoate prepn soluble guanylate cyclase stimulator;  
 cardiovascular agent carboxybenzylalkanoate prepn; angina pectoris  
 treatment carboxybenzylalkanoate prepn; heart failure treatment  
 carboxybenzylalkanoate prepn; ischemia treatment carboxybenzylalkanoate  
 prepn  
 IT Heart, disease  
 (angina pectoris, treatment; prepn. of carboxybenzylalkanoates as  
 stimulators of sol. guanylate cyclase)  
 IT Vein  
 (disease, treatment; prepn. of carboxybenzylalkanoates as stimulators  
 of sol. guanylate cyclase)  
 IT Heart, disease  
 (failure, treatment; prepn. of carboxybenzylalkanoates as stimulators  
 of sol. guanylate cyclase)  
 IT Antiarteriosclerotics  
 Anticoagulants  
 Antihypertensives  
 (prepn. of carboxybenzylalkanoates as stimulators of sol. guanylate  
 cyclase)  
 IT Ischemia  
 (treatment; prepn. of carboxybenzylalkanoates as stimulators of sol.  
 guanylate cyclase)  
 IT 329980-04-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (a fprepn. of carboxybenzylalkanoates as stimulators of sol. guanylate  
 cyclase)  
 IT 14047-53-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (a ohprepn. of carboxybenzylalkanoates as stimulators of sol. guanylate  
 cyclase)  
 IT 329984-94-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (nod nprepn. of carboxybenzylalkanoates as stimulators of sol.  
 guanylate cyclase)  
 IT 329978-72-5P 329978-73-6P 329978-74-7P 329978-75-8P 329978-76-9P  
 329978-77-0P 329978-78-1P 329978-79-2P 329978-80-5P 329978-81-6P  
 329978-82-7P 329978-83-8P 329978-84-9P 329978-85-0P 329978-88-3P

329978-89-4P 329978-90-7P 329978-91-8P 329978-92-9P 329978-93-0P  
 329978-94-1P **329978-95-2P** 329978-96-3P 329978-97-4P  
 329978-98-5P 329978-99-6P 329979-00-2P 329979-01-3P 329979-02-4P  
 329979-03-5P 329979-04-6P 329979-05-7P 329979-06-8P 329979-07-9P  
 329979-08-0P 329979-09-1P 329979-10-4P 329979-11-5P 329979-12-6P  
 329979-13-7P 329979-14-8P 329979-15-9P 329979-16-0P 329979-17-1P  
 329979-18-2P 329979-19-3P 329979-20-6P 329979-21-7P 329979-22-8P  
 329979-23-9P 329979-24-0P 329979-25-1P 329979-26-2P 329979-27-3P  
 329979-28-4P 329979-29-5P 329979-30-8P 329979-31-9P 329979-32-0P  
 329979-33-1P 329979-34-2P 329979-35-3P 329979-36-4P 329979-37-5P  
 329979-38-6P 329979-39-7P **329979-40-0P** 329979-41-1P  
 329979-42-2P 329979-43-3P 329979-44-4P 329979-45-5P 329979-46-6P  
 329979-47-7P 329979-48-8P 329979-49-9P **329979-50-2P**  
 329979-51-3P **329979-52-4P 329979-53-5P**  
**329979-54-6P** 329979-55-7P 329979-56-8P 329979-57-9P  
 329979-58-0P 329979-59-1P **329979-60-4P** 329979-61-5P  
 329979-62-6P 329979-63-7P 329979-64-8P 329979-65-9P 329979-66-0P  
 329979-67-1P 329979-68-2P 329979-69-3P 329979-70-6P 329979-71-7P  
 329979-72-8P 329979-73-9P 329979-74-0P 329979-75-1P 329979-76-2P  
 329979-77-3P 329979-78-4P 329979-79-5P 329979-80-8P 329979-81-9P  
 329979-82-0P 329979-83-1P 329979-84-2P 329979-85-3P 329979-86-4P  
 329979-87-5P 329979-88-6P 329979-89-7P 329979-90-0P 329979-91-1P  
 329979-92-2P 329979-93-3P 329979-94-4P 329979-95-5P 329979-96-6P  
 329979-97-7P 329979-98-8P 329979-99-9P 329980-00-9P 329980-01-0P  
 329980-02-1P 329980-03-2P 329980-05-4P 329980-06-5P 329980-07-6P  
 329980-08-7P 329980-09-8P 329980-10-1P 329980-11-2P 329980-12-3P  
 329980-13-4P 329980-14-5P 329980-15-6P 329980-16-7P 329980-17-8P  
 329980-18-9P 329980-19-0P 329980-20-3P 329980-21-4P 329980-22-5P  
 329980-23-6P 329980-24-7P 329980-25-8P 329980-26-9P 329980-27-0P  
 329980-28-1P 329980-29-2P 329980-30-5P 329980-31-6P 329980-32-7P  
 329980-33-8P 329980-34-9P 329980-35-0P 329980-36-1P 329980-37-2P  
 329984-93-2P 329984-95-4P **329984-96-5P** 329985-07-1P  
 330184-18-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)

(prepn. of carboxybenzylalkanoates as stimulators of sol. guanylate cyclase)

IT 62-53-3, Aniline, reactions 90-01-7, 2-Hydroxybenzyl alcohol 90-02-8, Salicylaldehyde, reactions 92-54-6, N-Phenylpiperazine 98-17-9, 3-Trifluoromethylphenol 99-76-3, Methyl 4-hydroxybenzoate 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-51-6, Benzyl alcohol, reactions 109-01-3 109-65-9, Butyl bromide 109-97-7, Pyrrole 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-24-0, 1,5-Dibromopentane 111-25-1, Hexyl bromide 111-83-1, Octyl bromide 111-95-5 112-82-3, Hexadecyl bromide 123-75-1, Pyrrolidine, reactions 150-76-5, 4-Methoxyphenol 346-06-5, 2-Trifluorobenzyl alcohol 349-75-7, 3-Trifluorobenzyl alcohol 456-41-7, 3-Fluorobenzyl bromide 612-16-8, 2-Methoxybenzyl alcohol 626-16-4, 1,3-Bis(chloromethyl)benzene 1571-08-0, Methyl 4-formylbenzoate 1722-07-2, 2-Benzylaminobenzyl alcohol 1736-74-9, 4-Trifluoromethoxybenzyl alcohol 1822-94-2 2567-29-5, 4-Phenylbenzyl bromide 2577-48-2, L-Proline methyl ester 2696-85-7, 2-Butylaniline 2759-28-6, N-Benzylpiperazine 2928-43-0, 2-Phenylbenzyl alcohol 2942-59-8, 2-Chloronicotinic acid 3095-95-2 3163-27-7, 1-Bromomethylnaphthalene 3240-94-6 4282-40-0, Heptyl iodide 4463-31-4, 4-Cyclohexylbenzyl chloride 4521-45-3 4771-31-7, 4-Chloromethyl-2-phenylthiazole 5006-62-2, 3-Ethoxycarbonylpiperidine



5653-67-8, 2,3-Dimethoxybenzyl alcohol 5680-79-5, Glycine methyl ester hydrochloride 6214-45-5, 4-Butoxybenzyl alcohol 6272-38-4, 2-Benzyloxyphenol 6436-90-4, N-Benzylglycine ethyl ester 6905-05-1 10133-20-7 13200-60-7, Sarcosine ethyl ester 13807-84-6, 2-Phenoxybenzyl alcohol 13826-35-2, 3-Phenoxybenzyl alcohol 13889-98-0, N-Acetylpiperazine 14469-83-1, 5-Phenylpentyl bromide 15862-72-3, 2-Ethoxycarbonylpiperidine 17325-26-7, 4-Methoxycarbonylimidazole 18880-00-7, 4-tert-ButylBenzyl bromide 19853-09-9, 2-Phenylbenzyl bromide 20012-63-9, 2-Benzyloxyaniline 25542-62-5, Ethyl 6-bromohexanoate 33524-31-1, 2,5-Dimethoxybenzyl alcohol 34932-07-5 35444-44-1, Adipic acid monomethyl ester chloride 39546-32-2, 4-Piperidinecarboxamide 54777-65-0, 4-Acetamidobenzyl chloride 60789-54-0 70340-04-4, 2-Hydroxybenzyltriphenylphosphonium bromide 73217-31-9 80676-35-3 85684-64-6 88489-87-6 103010-41-9 107355-79-3, 2-(5-Bromopentyl)furan 108683-50-7 111818-34-9 126907-57-1 126907-58-2 142837-88-5, 2-(5-Bromopentyl)thiophene 150253-59-1 226250-00-6 242812-04-0 287176-81-2 329980-73-6 329980-74-7 329980-75-8 329980-76-9 329980-77-0 329980-78-1 329980-79-2 329980-80-5 329980-81-6 329980-82-7 329980-83-8 329980-84-9 329984-92-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of carboxybenzylalkanoates as stimulators of sol. guanylate cyclase)

IT 3351-71-1P 6513-49-1P 14178-18-8P 25224-32-2P 64820-07-1P  
87328-76-5P 89820-49-5P 116585-12-7P 135055-35-5P 137393-20-5P  
329980-38-3P 329980-39-4P 329980-40-7P 329980-41-8P 329980-42-9P  
329980-43-0P 329980-44-1P 329980-45-2P 329980-46-3P 329980-47-4P  
329980-48-5P 329980-49-6P 329980-50-9P 329980-51-0P 329980-52-1P  
329980-53-2P 329980-54-3P 329980-56-5P 329980-57-6P 329980-58-7P  
329980-59-8P 329980-60-1P 329980-61-2P 329980-62-3P 329980-63-4P  
329980-64-5P 329980-65-6P 329980-66-7P 329980-67-8P 329980-68-9P  
329980-69-0P 329980-70-3P 329980-71-4P 329980-72-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of carboxybenzylalkanoates as stimulators of sol. guanylate cyclase)

IT 9054-75-5, Guanylate cyclase

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(sol. guanylate cyclase stimulators; prepn. of carboxybenzylalkanoates as stimulators of sol. guanylate cyclase)

IT 329978-95-2P 329979-40-0P 329979-50-2P  
329979-52-4P 329979-53-5P 329979-54-6P  
329979-60-4P 329984-96-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of carboxybenzylalkanoates as stimulators of sol. guanylate cyclase)

RN 329978-95-2 HCAPLUS

CN Benzeneheptanoic acid, .epsilon.-[ (1E)-2-[2-([1,1'-biphenyl]-4-ylmethoxy)phenyl]ethenyl]-4-carboxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 329979-40-0 HCAPLUS

CN Benzeneheptanoic acid, .epsilon.-[(1E)-2-[2-([1,1'-biphenyl]-2-ylmethoxy)phenyl]ethenyl]-4-carboxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 329979-50-2 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[[4-[2-(trifluoromethyl)-4-thiazolyl]phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 329979-52-4 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[[4-[(1E)-2-phenylethenyl]phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 329979-53-5 HCAPLUS

CN Benzeneheptanoic acid, .epsilon.-[(1E)-2-[2-[[4-(acetylamino)phenyl]methoxy]phenyl]ethenyl]-4-carboxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 329979-54-6 HCAPLUS

CN Benzeneheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[[4-(5-methyl-2-benzoxazolyl)phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 329979-60-4 HCAPLUS

CN Benzenheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[[4-(phenylamino)carbonyl]phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 329984-96-5 HCAPLUS

CN Benzenheptanoic acid, 4-carboxy-.epsilon.-[(1E)-2-[2-[(4-cyclohexylphenyl)methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

